At a glance
Established by Integra Holdings in 2018, BacoCure is developing a novel bacterial product for local therapy (intravesicular) of non-muscle invasive bladder cancer (NMIBC) patients.
The platform was developed by Prof. Ofer Mandelboim, Prof. Gilad Bachrach, Prof. Vladimir Yutkin and Dr. Hamutal Gur from the Hebrew University and Hadassah Medical Center.
The global market for NMIBC is estimated to reach $2 billion in 2026, with increasing market share and sales of novel antibiotics developed and marketed by major pharma companies
The lead product of BacoCure is a novel mutated and inactivated uropathogenic bacteria that demonstrated impressive anti-tumor effects via a novel and differentiated mechanism of action with better safety profile compared to standard of care, BCG.
The product is at advanced preclinical development.
Extensive business development activity is ongoing, to support further development of the technology